Click on the JSmol tab to take a closer look at how GLP-1 (PDB 6X18), semaglutide (PDB 7KI0), tirzepatide (PDB 7FIM), and orforglipron (PDB 6XOX) are able to stabilize the active form of the GLP-1 receptor, and compare these structures to that of the inactive GLP-1 receptor (PDB 6LN2)
Glucagon-like peptide-1 (GLP-1) receptor agonists are a family of antihyperglycemic drugs that have demonstrated potent HbA1c reduction, low risk of hypoglycemia, with associated weight reduction, and proven cardiovascular and renal benefits.24 In this review we describe this type of drugs, their cardiovascular and renal benefits, as well as their clinical potential in patients with DKD, especially with the new oral semaglutide formulation, now available on the market
So, how do clinicians Read More Initiating GLP-1 Therapy Through Telehealth: What Clinicians Need to Monitor May 5, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 1,586 views As virtual care becomes more common, many clinicians now initiate GLP-1 receptor agonist therapy remotely
B 114 , 78307843 (2010)
And for many people, it does reduce the pull toward alcohol
Wegovy is licensed for chronic weight management